Is CG Oncology, Inc. Common stock (CGON) overvalued? · $4.74B cap
CG Oncology, Inc. Common stock (CGON) is a biotechnology company listed on US.
This page asks whether CG Oncology, Inc. Common stock (CGON) looks expensive on cached numbers — not a short thesis.
No cached income statement for CGON, so there is no earnings base to call rich or cheap.
CGON currently screens at market cap $4.74B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CGON 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CGON stock page for the full model, not this heading.
Not investment advice.